Already in June this year, Terraplasma Medical and Viromed announced a exclusive distribution cooperation This was followed by the takeover by the Viromed GroupViromed's acquisition of Terraplasma Medical is intended to significantly intensify and further expand the existing collaboration. This will particularly apply to the broad marketing of the Plasma Care product range, according to Uwe Perbandt, CEO of Viromed. Jens Kirsch, CEO of Terraplasma Medical, is also pleased to have gained a strong sales and financial partner in Viromed. Julia Zimmermann, CEO of Terraplasma, intends to continue working with Terraplasma Medical to develop innovative medical products for various medical applications and successfully establish them on the market.
Cold atmospheric plasma physicochemically inactivates bacteria, multi-resistant pathogens, viruses, and even fungi with high effectiveness. Its use in medical technology can revolutionize, complement, and in some cases even replace conventional treatment methods, for example, in surgery for postoperative wounds to prevent infections.
Further expansion of the Plasma Care product line
In healthcare, cold atmospheric plasma offers a treatment option for chronic, often long-standing, and non-healing wounds. Cold plasma treatment can reduce the need for antibiotics or cortisone. The Plasma Care product line developed by Terraplasma Medical for this purpose, which uses cold atmospheric plasma in medical technology, will be further expanded in the future.
According to the company, clinical experience in recent years has shown that, in addition to its bactericidal and healing effects, this new form of therapy offers additional benefits for the healthcare system: for example, it can reduce nursing and dressing costs, and prevent complications and longer hospital stays during postoperative use. Reduced use of antibiotics can prevent resulting resistance, and fewer anti-inflammatory drugs can be used in dermatology.
